Among the 19 potential TAA targets, 4 TAAs showed significantly higher autoantibody frequencies in the HCC group compared to the NHS group, which are DNMT3A, p16, HSP60, and HSPA5. This evidence concerns the gene CDKN2A and hepatocellular carcinoma.